MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Ticagrelor and Peripheral Arterial Disease

Phase 4
Terminated
Conditions
Peripheral Arterial Disease
Interventions
Procedure: Percutaneous Peripheral Intervention
Device: Optical Coherence Tomography
Other: Ankle Brachial Index
Other: Six minute walk distance
Drug: Aspirin + Ticagrelor
Drug: Aspirin
First Posted Date
2015-04-02
Last Posted Date
2019-01-11
Lead Sponsor
Arkansas Heart Hospital
Target Recruit Count
26
Registration Number
NCT02407314
Locations
🇺🇸

Arkansas Heart Hospital, Little Rock, Arkansas, United States

Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis

Phase 4
Conditions
Percutaneous Coronary Intervention
Interventions
Drug: 12 months of P2Y12 receptor antagonist
Drug: 24 months of P2Y12 receptor antagonist
Drug: Aspirin
First Posted Date
2015-03-30
Last Posted Date
2015-03-30
Lead Sponsor
Beijing Anzhen Hospital
Target Recruit Count
1000
Registration Number
NCT02402491
Locations
🇨🇳

Beijing Anzhen Hospital, Beijing, Beijing, China

Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study

Phase 1
Completed
Conditions
Cardiovascular Disease Risk in HIV Patients
Endothelial Function
Interventions
Drug: Aspirin
Drug: Placebo
First Posted Date
2015-03-27
Last Posted Date
2016-01-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
91
Registration Number
NCT02401269
Locations
🇲🇼

Lighthouse Trust, Lilongwe, Malawi

Aspirin and Enoxaparin for VTE in Trauma

Phase 4
Terminated
Conditions
Thromboprophylaxis
Trauma
Venous Thromboembolism
Interventions
First Posted Date
2015-03-24
Last Posted Date
2019-11-19
Lead Sponsor
University of Miami
Target Recruit Count
31
Registration Number
NCT02396732
Locations
🇺🇸

Ryder Trauma Center, Miami, Florida, United States

ASPirin Intervention for the REDuction of Colorectal Cancer Risk

Not Applicable
Active, not recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Placebo for Aspirin
Drug: Aspirin
First Posted Date
2015-03-20
Last Posted Date
2024-03-21
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
180
Registration Number
NCT02394769
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Gefitinib Combined With Thalidomide to Treat NSCLC

Phase 2
Conditions
NSCLC
Interventions
First Posted Date
2015-03-12
Last Posted Date
2015-03-12
Lead Sponsor
Bai Jun
Target Recruit Count
380
Registration Number
NCT02387086

Simplified Anti-Thrombotic Therapy for FFR

Not Applicable
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2015-03-10
Last Posted Date
2017-02-03
Lead Sponsor
Odessa Heart Institute
Target Recruit Count
300
Registration Number
NCT02384070

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

Phase 1
Completed
Conditions
Cardiovascular Disease
Interventions
Drug: Aspirin
Drug: Durlaza™
First Posted Date
2015-02-25
Last Posted Date
2015-08-06
Lead Sponsor
New Haven Pharmaceuticals, Inc.
Target Recruit Count
41
Registration Number
NCT02370680
Locations
🇺🇸

Platelet and Thrombosis Research, LLC, Baltimore, Maryland, United States

Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Not Applicable
Conditions
Kawasaki Disease
Interventions
First Posted Date
2015-02-10
Last Posted Date
2016-02-02
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
300
Registration Number
NCT02359643

Peri-operative Aspirin Continuation Versus Discontinuation

Phase 4
Terminated
Conditions
Urinary Bladder Neoplasms
Hematuria
Interventions
First Posted Date
2015-01-29
Last Posted Date
2019-04-08
Lead Sponsor
Rabin Medical Center
Target Recruit Count
50
Registration Number
NCT02350543
Locations
🇮🇱

Rabin Medical Center, Petah Tikva, Israel

© Copyright 2025. All Rights Reserved by MedPath